Founded in 1992, Sands Capital is an independent, employee-owned investment management firm based in Arlington, Virginia. It specializes in fundamental, bottom-up research to identify high-quality growth businesses globally, from early-stage private companies to leading public entities across various sectors.
Executive Managing Director, Senior Portfolio Manager and Research Analyst
Christopher Eng
Principal
Scott Frederick
Managing Director
Kumar Gautam
Partner
Michael Ginder
Partner
Michael Graninger
Managing Partner
Michael Graninger
Partner
Nicholas Graziano
Principal, Portfolio Services
David Levanson
Senior Portfolio Manager, Research Analyst and Executive Managing Director
Barron Martin Jr.
Managing Partner
Barron Martin
Research Analyst
Annie McCormick
Director, Client Service
Mark McGovern
Venture Partner
Dana McNamara
Executive Managing Director and Chief Administrative Officer
Jake Merrill
Principal
Gene Riechers
Venture Partner
Frank M. Sands, Jr.
CEO, CIO
Marina Serenbetz
Partner
Shreya Singh
Associate
Erin Soule
Managing Director and Head of Private Markets Finance and Operations
Michael Sramek
Managing Director, Research Analyst and Senior Portfolio Manager
Christy Steele
Principal
Past deals in Infants
Vitara Biomedical
Series B in 2024
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Vitara Biomedical
Series B in 2022
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.